港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医药外包概念

1,673.767

+16.3240.98%

涨家数：2

跌家数：6

平家数：- -

市盈率：- -

高：1,679.878

开：1,657.294

低：1,644.734

收：1,657.443

数据加载中...

总览新闻资讯

山东京卫制药有限公司药品申请临床试验默示许可获受理

安徽中盛溯源生物科技有限公司药品申请临床试验默示许可获受理

和径医药科技（上海）有限公司药品申请临床试验默示许可获受理

四川美大康佳乐药业有限公司药品申请临床试验默示许可获受理

士泽生物医药（上海）有限公司药品申请临床试验默示许可获受理

瑞博生物港交所递表小核酸药物龙头企业有望登陆资本市场

泰格医药获易方达基金增持37.21万股每股作价约26.19港元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1576/news?page=10"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1576","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","market":"HK","secType":"PLATE","nameCN":"医药外包概念","latestPrice":1673.7673,"timestamp":1746778085274,"preClose":1657.4429,"halted":0,"volume":61176192,"delay":0,"changeRate":0.009849,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":16.324463,"latestTime":"05-09 16:00:00","open":1657.2936,"high":1679.8776,"low":1644.7339,"amount":1282430398,"amplitude":0.021204,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747013400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1746754200000,1746763200000],[1746766800000,1746777600000]],"pbRate":1.995923,"peRate":9.57354,"turnoverRate":0.005217,"increases":2,"decrements":6,"flats":0,"marketCap":354862028800,"floatMarketCap":156066048640},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1576\",,,,,undefined,":{"symbol":"BK1576","high":1679.8776,"amplitude":0.021204,"preClose":1657.4429,"low":1644.7339,"pbRate":"1.995923","latestPrice":1673.7673,"volume":61176192,"delay":0,"open":1657.2936,"prevYearClose":1395.7731,"prevWeekClose":1741.969,"prevMonthClose":1656.921,"prevQuarterClose":1941.338,"fiveDayClose":1656.921,"twentyDayClose":1379.13,"sixtyDayClose":1588.191,"secType":"PLATE","market":"HK","turnoverRate":0.005217,"peRate":9.57354,"marketCap":354862028800,"floatMarketCap":156066048640,"timestamp":1746778085274,"nameCN":"医药外包概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1576\",,,,undefined,":{"bkCode":"BK1576","up":2,"down":6,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1576\",pageSize:20,pageCount:10,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2530835584","title":"山东京卫制药有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835584","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835584?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，山东京卫制药有限公司联合申请药品“米诺地尔泡沫剂（男用）”，获得临床试验默示许可，受理号CYHL2500041。山东京卫制药有限公司，成立于1993年，位于泰安市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，山东京卫制药有限公司共对外投资了2家企业，参与招投标项目1749次，知识产权方面有商标信息146条，专利信息129条，此外企业还拥有行政许可182个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","03347","BK1191","BK1576","BK1141","BK1583","01477"],"gpt_icon":0},{"id":"2530835324","title":"安徽中盛溯源生物科技有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530835324","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530835324?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，安徽中盛溯源生物科技有限公司、中盛溯源（广州）生物科技有限公司联合申请药品“NCR201注射液”，获得临床试验默示许可，受理号CXSL2500126。安徽中盛溯源生物科技有限公司，成立于2016年，位于合肥市，是一家以从事医药制造业为主的企业。通过天眼查大数据分析，安徽中盛溯源生物科技有限公司共对外投资了5家企业，参与招投标项目11次，知识产权方面有商标信息60条，专利信息30条，此外企业还拥有行政许可11个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","159837","BK1141","BK1576","03347"],"gpt_icon":0},{"id":"2530483315","title":"和径医药科技（上海）有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530483315","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530483315?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，和径医药科技（上海）有限公司联合申请药品“HJ-002-03片”，获得临床试验默示许可，受理号CXHB2500069。和径医药科技（上海）有限公司，成立于2017年，位于上海市，是一家以从事科技推广和应用服务业为主的企业。通过天眼查大数据分析，和径医药科技（上海）有限公司专利信息14条，此外企业还拥有行政许可3个。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09939","BK1515","159938","BK1576","03347","BK1161","BK1583","BK1574","BK1141"],"gpt_icon":0},{"id":"2530365483","title":"四川美大康佳乐药业有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530365483","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530365483?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，四川美大康佳乐药业有限公司联合申请药品“甘露醇山梨醇注射液”，获得临床试验默示许可，受理号CYHL2500033。通过天眼查大数据分析，四川美大康佳乐药业有限公司共对外投资了1家企业，参与招投标项目423次，知识产权方面有商标信息25条，专利信息22条，此外企业还拥有行政许可191个。主要股东信息显示，四川美大康佳乐药业有限公司由四川蓝剑投资管理有限公司持股100%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925395.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","BK1576","BK1141","BK1583"],"gpt_icon":0},{"id":"2530248331","title":"士泽生物医药（上海）有限公司药品申请临床试验默示许可获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2530248331","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530248331?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 13:01","pubTimestamp":1745730068,"startTime":"0","endTime":"0","summary":"4月27日，据CDE官网消息，士泽生物医药（上海）有限公司、士泽生物医药（苏州）有限公司联合申请药品“XS228细胞注射液”，获得临床试验默示许可，受理号CXSL2500121。士泽生物医药（上海）有限公司，成立于2021年，位于上海市，是一家以从事专业技术服务业为主的企业。主要股东信息显示，士泽生物医药（上海）有限公司由士泽生物医药（苏州）有限公司持股100%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/27130149925394.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1141","399441","BK1583","03347","161726","BK1576"],"gpt_icon":0},{"id":"2530410672","title":"瑞博生物港交所递表 小核酸药物龙头企业有望登陆资本市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2530410672","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530410672?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 09:32","pubTimestamp":1745717567,"startTime":"0","endTime":"0","summary":"根据招股书，瑞博生物目前有六款自研siRNA药物处于临床试验阶段，涉及七种适应症，其中四款进入2期临床试验；另有超过20个临床前资产持续推进中。血栓性疾病已成为全球主要死因之一，全球四分之一死亡与血栓性疾病相关。截止目前，全球尚未批准任何siRNA药物用于治疗慢性乙型肝炎。瑞博生物作为国内最早专注小核酸药物开发的企业之一，建立了强大的全球知识产权组合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1141","BK1191","BK1583","03347","BK1574","BK1576"],"gpt_icon":0},{"id":"2530105812","title":"泰格医药获易方达基金增持37.21万股 每股作价约26.19港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2530105812","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530105812?lang=zh_cn&edition=fundamental","pubTime":"2025-04-27 08:32","pubTimestamp":1745713920,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，4月22日，易方达基金增持泰格医药（03347）37.21万股，每股作价26.185港元，总金额约为974.34万港元。增持后最新持股数目为770.37万股，持股比例为6.26%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-27/doc-ineuqcqi7921881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1141","03347","BK0174","BK1576","BK0077","LU1146622755.USD","300347","BK1583","BK0028","BK0216","LU1820825898.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":187,"code":"91000000","status":"200"}]}}